oral consumption ensures maximum benefits
In many cases, individuals may transition to a maintenance phase where injections are administered less frequently, such as once every two weeks or once a month
"FDA Response to three Citizen Petitions against biosimilars" (PDF), FDA , 30 May 2006, archived from the original (PDF) on June 19, 2006, retrieved 23 November 2015 In 2023, the FDA approved a different sustained-release form of growth hormone, Sogroya (somapacitan-beco) (Novo) for both pediatric patients (2.5 years and older) and adult patients, whom have growth failure due to inadequate secretion of endogenous growth hormone (rHGH)
Schedule your personalized treatment appointment now
Instead, it must be gotten from food or supplements